期刊文献+

晚期非小细胞肺癌的化放疗序贯治疗 被引量:2

Sequential chemo-radiation therapy for advanced non-small-cell lung cancer
原文传递
导出
摘要 目的探讨吉西他滨联合顺铂治疗晚期非小细胞肺癌3周方案并序贯化放疗的疗效和不良反应。方法经病理和细胞学证实的晚期非小细胞肺癌患者,既往未进行化疗和放疗,临床上有可测量病灶(根据WHO标准),美国东部肿瘤协作组(ECOG)评分为0~2分,肝、肾功能基本正常。均给予吉西他滨和顺铂的联合化疗并序贯化放疗方案治疗。按照WHO的标准评价疗效和不良反应,并随访生存期。结果共入组43例患者,其中39例可评价疗效:19例(48.72%)部分缓解、13例(33.33%)病情稳定和7例(17.95%)疾病进展。生存期为3.7~21.4个月,中位生存期为10.1个月。主要的不良反应为血液毒性,表现为白细胞、中性粒细胞、血小板和血红蛋白下降;其次为消化道症状。结论吉西他滨联合顺铂治疗晚期非小细胞肺癌3周方案并序贯化放疗是晚期非小细胞肺癌的标准一线化疗方案之一,患者可较好耐受。 Objective To explore the curative effect and adverse reaction of gemcitabine combined with cisplatin 3-week regimen combined with sequential chemo-radiation therapy for patients with advanced non-small-cell lung cancer (NSCLC). Methods The patients with advanced NSCLC verified by pathology and cytology between January 2000 and October 2005 were chosen, who didn't undertake chemotherapy and radiotherapy in the past. They were found to have clinically measurable focus (based on WHO standard), ECOG score ranged from 0 to 2, liver and kidney's function were basically normal. They were all given gemcitabine combined with cisplatin 3-week regimen combined with sequential chemo-radiation therapy. Curative effect and adverse reaction were evaluated by WHO standard. Their survival time was followed up. Results Forty three cases were elected into the study group of those, curative effect in 39 cases could be evaluated. Nineteen of 39 cases were PR (48.72%), 13 cases were SD (33.33%) and 7 cases were PD (17.95%). Neutral survival time was 10.1 months, ranging from 3.7 to 21.4 months. The main adverse reaction was hematologic toxicity. The manifestation were WBC, neutrophile granulocyte, blood platelet and hemoglobin all decreased, then was digestive canal symptom. Conclusion It is an effective and well-tolerated treatment protocol gemcitabine combined with cisplatin 3-week regimen combined with sequential chemo-radiation therapy for patients with advanced NSCLC.
出处 《中国医师进修杂志》 2006年第9期1-4,共4页 Chinese Journal of Postgraduates of Medicine
关键词 吉西他滨 顺铂 化疗 非小细胞肺癌 序贯化放疗 Gemcitabine Cisplatin Chemotherapy Non-small-cell lung cancer Sequential chemo-radiation therapy
  • 相关文献

参考文献15

  • 1Ginsberg RJ,Vokes EE,Rosenzweig K.Non-small-cell lung eancer//de Vita VT,Hellman S,Rosenberg SA.Cancer:principles and practice of oncology.6th ed.Philadelphia:Lippin Gott Raven Co,2001:925-983.
  • 2Socinski MA,Morris DE,Masters GA,et al.Chemotherapeutic management of stage Ⅳ non-small cell lung cancer.Chest,2003,123(Suppl 1):s226-s243.
  • 3Curran WJ,Scell CB,Langer C J,et al.Long-term benefit is observed in a phase Ⅲ comparison of sequential vs concurrent chemoradiation for patients with unresected stage Ⅲ NSCLC:RTOG 9410.Proc Am Soc Clin Oncol,2003,22:621.
  • 4Fournel P,Perol M,Robinet G,et al.A randomized phase Ⅲ trial of sequential chemo-radiotherapy versus concurrent chemo-radiotherapy in locally advanced non small cell lung cancer (GLOT GFPC NPC 9501 study).Proc Am Soc Clin Oncol,2001,20:312.
  • 5Zatloukal P,Petruzelka L,Zemanova M,et al.Concurrent versus sequential chemo-radiotherapy with cisplatin and vinorelhine in locally advanced non-small-cell lung cancer:a randomized study.Lung Cancer,2004,46(1):87-98.
  • 6吴一龙,蒋国梁,廖美琳,王绿化,周清华,杨学宁,孙燕,无.局部晚期非小细胞肺癌化放疗共识[J].循证医学,2005,5(3):186-188. 被引量:36
  • 7Stephens RJ,Fairlamb D,Gower N,et al.The big lung trial:determining the value of cisplatin-based chemotherapy for all patients with non-small-cell lung cancer.Preliminary results in the supportive care setting.Proc Am Soc Clin Oncol,2002,21:1161.
  • 8Barton BM.Gemcitabine:a pharmaceutical and clinical overview.Cancer,1999,22 (2):176-177.
  • 9van Moorsel CJ,Pinedo HM,Veerman G,et al.Mechanism of synergism between cisplatin and gemcitsbine in ovarian and non-small-cell lung cancer cell lines.Br J Cancer,1999,80(7):981-990.
  • 10Shord SS,Faucette SR,Gillenwater HH,et al.Gemcitsbine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer.Cancer Chemother Pharmacol,2003,51 (4):328-336.

二级参考文献11

  • 1施春雷,韩宝惠.ASCO不可手术切除的非小细胞肺癌治疗指南——2003新版推荐指南[J].循证医学,2004,4(2):115-124. 被引量:114
  • 2吴一龙,周清华,廖美琳,蒋国樑,张明和,张熙曾,王俊,支修益,陈刚,王思愚,杨学宁,孙燕,无.各期非小细胞肺癌外科治疗临床指引[J].中国肺癌杂志,2004,7(5):399-403. 被引量:14
  • 3[1]Shord SS, Fancette SR, Gillenwater HH, et al. Gemcitabinepharmacokinetics and interaction with paclitaxel in patients withadvanced non- small- cell lung cancer[ J]. Cancer ChemotherPharmacol, 2003,51: 328.
  • 4[2]Highlights from the 10th World Conference on Lung CancerIR]. Vancouver, British Columbia, Canada, August 10 - 14,2003. In: Clin Lung Cancer, 2003,5 (3): 142.
  • 5[3]Bretti S, Manzin E, Loddo C, et al. Gemcitabine plus cisplatinin the treatment of patients with advanced non - small cell lungcancer, a phase II study[ J ]. Anticancer Res, 2002,22: 3 039.
  • 6[4]Migliorino MR, De Marinis F, Nelli F, et al. A 3 - weekschedule of gemcitabine plus cisplatin as induction chemot-herapy for stage [1I non - small cell lung cancer [ J ]. LungCancer, 2002,35:319.
  • 7[5]Jassem J, Krzakowski M, Roszkowski K, et al. A phase Iistudy of gemcitabine plus cisplatin in patients with advancednon- small cell lung cancer: clinical outcomes and quality oflife[J]. Lung Cancer, 2002,35:73.
  • 8[6]Thongprasert S, Chewaskulyong B, Pothirat C. Combination ofgemcitabine and cisplatin in advanced non - small cell lungcancer[ J]. J Med Assoc Thai, 2001,84:397.
  • 9[7]Kusaba H, Tamura T, Shimoyama T, et al. Phase I / II studyof 3 - week cycle cisplating - gemcitabine in advanced non -small cell lung cancer[J]. Jpn J Clin Oncol, 2002,32:43.
  • 10[8]Kunikane H, Kurita Y, Watanabe K, et al. A study of thecombination of gemcitabine hydrochloride (LY188011) andcisplatin in non - small - cell lung cancer: 3 - week schedule[ J]. lnt J Clin Oncol, 200 l, 6: 284.

共引文献45

同被引文献22

  • 1王彬,张湘茹,储大同.易瑞沙在晚期非小细胞肺癌化疗失败后的作用[J].中华肿瘤杂志,2004,26(12):742-745. 被引量:53
  • 2刘爱华,黄玮,肖绍文,谭源福,吴中学.微血管密度和MMP-9与垂体腺瘤侵袭性相关性研究[J].医师进修杂志(外科版),2005,28(5):18-20. 被引量:1
  • 3张莉,于世英.吉非替尼单药治疗晚期非小细胞肺癌[J].中华肿瘤杂志,2006,28(7):539-541. 被引量:37
  • 4Suzuki H,Aoshiba K,Yokohori N,et al.Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis.Cascer Res,2003,63(16):5054-5059.
  • 5Ciardiello F,Caputo R,Bianco R,et al.Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa),a selective epidermal growth factor receptor tyrosine kinase inhibitor.Clin Cancer Res,2001,7(5):1459-1465.
  • 6Thatcher N,Chang A,Parikh P,et al.Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer:results from a randomised,placebo-controlled,multicentre study (Iressa Survival Evaluation in Lung Cancer).Lancet,2005,366(9496):1527-1537.
  • 7Mok TS,Wu YL,Thongprasert S,et al.Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinorma.N Engl J Med,2009,361(10):947-957.
  • 8Ezzati M, Henley S J, Lopez AD, et al. Role of smoking in global and regional cancer epidemiology:current patterns and data needs. Int J Cancer, 2005,116(6) :963-971.
  • 9Jemal A,Thomas A,Murray T,et al. Cancer statistics,2002. CA Cancer J Clin, 2002,52( 1 ) : 23- 47.
  • 10Masuda M, Kikuchi S, Maruyama T, et al. Tumor suppressor in lung (TSLC)1 suppresses epithelial cell scattering and tubulogenesis. J Biol Chem,2005,280(51 ): 164-171.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部